Sodium Hydroxide → HCID 86661293, Verbindung

HRID 1685031

Reaktionsgleichung

Reaktionsgleichung von HRID 1685031
[Cl:1][C:2]1[CH:3]=[C:4]([CH:17]=[CH:18][C:19]=1[Cl:20])[CH2:5][NH:6][C:7]([NH:9][C:10]1[S:11][CH:12]=[C:13]([CH:15]=O)[N:14]=1)=[O:8].[OH-].[Na+].[NH2:23][CH2:24][CH2:25][CH2:26][P:27](=[O:30])([OH:29])[OH:28].C([BH3-])#N.[Na+]>CO.[Br-].C([N+](CCCC)(CCCC)CCCC)CCC>[Cl:1][C:2]1[CH:3]=[C:4]([CH:17]=[CH:18][C:19]=1[Cl:20])[CH2:5][NH:6][C:7](=[O:8])[NH:9][C:10]1[S:11][CH:12]=[C:13]([CH2:15][NH:23][CH2:24][CH2:25][CH2:26][P:27](=[O:28])([OH:30])[OH:29])[N:14]=1

Komponenten

7

Versuchsvorschrift

300 mg of 1-(3,4-dichlorobenzyl)-3-(4-formylthiazol-2-yl) urea was dissolved in 5 ml MeOH. 1.0 eq. of tetrabutylammonium bromide and 1.0 eq. of sodium hydroxide were added followed by addition of 1.0 eq. of 3-aminopropylphosphonic acid. To the mixture, 3.0 eq. of sodium cyanoborohydride was added and the reaction was stirred at room temp. overnight. The reaction mixture was loaded to reverse phase column and purified by HPLC to give 3-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methylamino)propylphosphonic acid.

Aufarbeitung

  1. custompurified by HPLC

Quellen und Nachweise

ORD-Eintrag
ord-34b40dc733d64cd18ec8505e2014876e
Quelldatensatz
uspto-grants-2012_04
Patentnummer
US08148380B2

Verknüpfte Notizen

Wird geladen…